Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
EARLY_PHASE1
28 participants
INTERVENTIONAL
2013-07-31
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of GLP-1 on Glucose Uptake in the Brain and Heart in Healthy Men During Hypoglycemia
NCT00418288
GLP-1 Infusion and Long-Time Fasting
NCT00285896
Glucagon-like Peptide-1 in Type 1 Diabetes
NCT04355832
Endothelial and Metabolic Effects of Glucagon-like Peptide-1 (GLP-1) in Coronary Circulation in Patients With Type 2 Diabetes Mellitus
NCT00923962
Glucagon-like Peptide 2 - a Glucose Dependent Glucagonotropic Hormone?
NCT03954873
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Glucagon-Like Peptide -1 (GLP-1) infusion
Infusion of GLP-1 during experimental period
Glucagon-Like Peptide- 1 (GLP-1) infusion
GLP-1 infusion during experimental period
Saline Infusion
Saline infusion during experimental period
Placebo Comparator: Saline Infusion
Saline infusion (placebo) during experimental period
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Glucagon-Like Peptide- 1 (GLP-1) infusion
GLP-1 infusion during experimental period
Placebo Comparator: Saline Infusion
Saline infusion (placebo) during experimental period
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 14 (7 males, 7 females) people with type 2 DM age 30-60 yr.
* For type 2 DM: HbA1c 6-10.0%
* No significant diabetic tissue complications (i.e. history of retinopathy, neuropathy, stasis ulcers, etc.)
* Body mass index \>25kg • m-2
Exclusion Criteria
18 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Maryland, Baltimore
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Stephen N. Davis, MBBS
Chairman of Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Stephen N Davis, MBBS
Role: PRINCIPAL_INVESTIGATOR
University of Maryland, Baltimore
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Maryland, Baltimore
Baltimore, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HP00055308
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.